<div id="readability-page-1"><div>Palleiko Benjamin L Chief Executive Officer of KalVista Pharmaceuticals Inc [KALV] filed a Form 4 on December 9, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:<div><table><tbody><tr><th>Date</th><th>Transaction</th><th>Shares</th><th>Price</th><th>Value</th></tr><tr><td>12/6/25</td><td>Exercise</td><td>15,625</td><td>$0.00</td><td>N/A</td></tr><tr><td>12/8/25</td><td>Surrender(1)</td><td>7,294</td><td>$16.51</td><td>$120,424</td></tr></tbody></table></div>Ending Holdings: 424,520 - Direct<ul><li>(1)</li><li>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</li></ul>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data. </div></div>

KALV

CEO Benjamin L Palleiko of KalVista Pharmaceuticals Inc filed a Form 4 with the SEC, disclosing changes in ownership. On December 6, 2025, he exercised 15,625 shares at $0.00, and on December 8, 2025, surrendered 7,294 shares at $16.51 to cover option exercise costs and tax liabilities. His ending holdings are 424,520 shares directly.

CEO Palleiko Acquires 8,331 Of KalVista Pharmaceuticals Inc [KALV]